Stock ANIK ANIKA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Anika Therapeutics, Inc.

Equities

ANIK

US0352551081

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
25.69 USD +0.71% Intraday chart for Anika Therapeutics, Inc. -0.66% +13.37%
Mar. 14 Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating MT
Mar. 13 Transcript : Anika Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024

Evolution of the average Target Price on Anika Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

af12256cb54a75a87.cIhwJVatitMNyZgECWBL13y_oqp3NLqxBZB8WKXzPQs.HMQJFnub75VhqKlXPRolmT_R9ZoYeMOJd_8uNNG3eTg9uAhuJcLyhGuH0Q~6cd56932fc5a0957a4a7d76241d650aa

Analyst Recommendations on Anika Therapeutics, Inc.

Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating MT
Barrington Ups Price Target on Anika Therapeutics to $29 From $28, Reiterates Outperform Rating MT
Barrington Ups PT on Anika Therapeutics to $28 From $24, Expecting JPR Business to Produce 'Double-digit, Top-line Growth', Maintains Outperform Rating MT
Barrington Upgrades Anika Therapeutics to Outperform From Market Perform, Saying 'Downdraft in Shares Seems Materially Overdone,' Price Target is $24 MT
Stephens Adjusts Price Target on Anika Therapeutics to $23 From $28, Maintains Equal-Weight Rating MT
Barrington Research Downgrades Anika Therapeutics to Market Perform From Outperform After Full-Year 2023 Forecast Below Expectations MT
Barrington Research Downgrades Anika Therapeutics to Market Perform From Outperform MT
Barrington Upgrades Anika Therapeutics to Outperform From Market Perform, Price Target is $31 MT
Stephens Reinstates Anika Therapeutics at Equalweight With $26 Price Target MT
Stephens Downgrades Anika Therapeutics to Equalweight from Overweight, Adjusts Price Target to $35 from $50 MT
Stephens Starts Anika Therapeutics at Overweight With $55 Price Target MT
Barrington Adjusts Price Target on Anika Therapeutics to $48 From $44, Keeps Outperform Rating MT
ANIKA THERAPEUTICS : UBS Starts Anika Therapeutics at Neutral With $46 Price Target MT
ANIKA THERAPEUTICS : Barrington Research Upgrades Anika Therapeutics to Outperform From Market Perform; Price Target is $43 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
25.69 USD
Average target price
30.33 USD
Spread / Average Target
+18.07%
High Price Target
37 USD
Spread / Highest target
+44.02%
Low Price Target
22 USD
Spread / Lowest Target
-14.36%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Anika Therapeutics, Inc.

Barrington Research
Stephens Inc.
UBS

Ratings for Anika Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ANIK Stock
  4. Consensus Anika Therapeutics, Inc.